Generic Drug Development CDMO

Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a comprehensive technical strategy that integrates qualitative and quantitative formulation sameness (Q1/Q2), […]

Introduction Impurity Control Strategies Under ICH Q3A and Q3B establish a risk-based regulatory framework used by global health authorities to

Introduction Outsourcing your first generic drug project to a CDMO requires a structured technical transition that covers candidate characterization, technology

Introduction Container Closure System Selection and Qualification for generic parenteral drug products involves the systematic evaluation and validation of primary

Introduction End-to-End ANDA Analytical Package Development for a complex generic suspension requires an integrated analytical framework that connects qualitative (Q1)

Introduction Technology Transfer from Innovator to Generic CDMO is a structured and highly regulated process involving the systematic translation of

Introduction: Generic Drug Development for Inhaled Drug Products requires a development strategy that connects formulation science, device engineering, analytical characterization,

Introduction Demonstrating bioequivalence for a Generic Topical Semisolid ANDA requires a comprehensive assessment of qualitative (Q1), quantitative (Q2), and structural

Introduction Executing compliant Impurity Control Strategies Under ICH Q3A and Q3B requires establishing scientific and toxicological parity with the Reference

Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a coordinated technical strategy that integrates qualitative and quantitative sameness (Q1/Q2), structural